Enumeral has raised $21.5 million in a private placement. According to terms of the transaction, the company sold 21.5 million shares at a price of $1 per share. Montrose Capital Partners led the financing with participation from founding investor Harris & Harris Group. Intuitive Venture Partners served as exclusive financial advisor while EDI Financial was the lead placement agent. Based in Cambridge, Mass., Enumeral develops developing antibody immunotherapies that help the immune system attack diseased cells. The company just completed a merger between Enumeral Biomedical Corp and a unit of Enumeral Biomedical Holdings (formerly known as Cerulean Group).

from PE Hub Blog http://ift.tt/UWtPTs